GPC3 and hepatocellular carcinoma: In contrast to that, cancer vaccines targeting individual tumor-associated antigens (TAAs), such as NY-ESO1, glypican-3 (GPC3), and alpha-fetoprotein (AFP), have met with limited success in HCC [189].